Maria Paola Simula

Maria Paola Simula

Auto-generated profile, based on publicly available information

Maria Paola Simula

Experimental and Clinical Pharmacology Unit, CRO Centro di Riferimento Oncologico, IRCCS National Cancer Institute, via F. Gallini 2, Aviano-PN 33081, Italy

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 November 2009 in International Journal of Oncology
Verified
Journal Article
Closed access
PDF file
COCorona
Corona
GCGiuseppe Corona
Giuseppe Corona
ELElisa De Lorenzo
Elisa De Lorenzo
CECaterina Elia
Caterina Elia
MSMaria Paola Simula
Maria Paola Simula
GTGiuseppe Toffoli
Giuseppe Toffoli
The principal aim of the present study consisted in the identification of the disregulated proteins associated with the development of hepatocellular carcinoma (HCC). The differences in protein expression between hepatocellular carcinoma (HCC) and the corresponding non-HCC liver tissues were investigated in a cohort of 20 patients using two-dimensional fluorescence difference in gel electrophoresis (2D-DIGE) coupled with mass spectrometry (MS). The up- and down-regulated protein spots that exhibited 1.5-fold difference signal intensity with statistical significance (p<0.05, t-test, confidence intervals 95%) were excised from the gel and identified by peptide mass fingerprinting using matrix assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS). Thirty-six protein spots corresponding to 29 different disregulated proteins, belonging to heterogeneous metabolic pathways, have been identified. Down-regulated proteins (n=23) were found superior in number than the up-regulated proteins (n=6). Detoxification, carbohydrate metabolism and amino acid biotrasformation represented the main disregulated pathways in HCC. Up-regulation of aldo-keto reductase 1C2, thioredoxin and transketolase, involved in metabolic and regulatory cellular processes including proliferation, differentiation and carcinogenesis were remarkable. These proteins could represent useful biomarkers to provide new insights into global pathophysiologic changes of HCC and for the development of new pharmacological approaches to HCC therapy.

4 November 2011
Verified
Book Chapter
Closed access
PDF file
MSMaria Paola Simula
Maria Paola Simula
ANAgata Notarpietro
Agata Notarpietro
GTGiuseppe Toffoli
Giuseppe Toffoli
Valli De ReValli De Re
Valli De Re

2 April 2009 in International Journal of Oncology
Verified
Journal Article
Closed access
PDF file
TOToffoli
Toffoli
MVMichele Visentin
Michele Visentin
MSMaria Paola Simula
Maria Paola Simula
FSFranca Sartor
Franca Sartor
APAlessandra Petrucco
Alessandra Petrucco
GTGiuseppe Toffoli
Giuseppe Toffoli
Multi-drug resistance (MDR) limits the effectiveness of chemotherapy. P-glycoprotein encoded by the MDR1 gene, is known to be implicated in MDR phenotype, but other factors could be determinant in MDR. The aim of this study was to investigate new molecular factors potentially associated with the MDR phenotype using a proteomic approach. Two dimensional fluorescence difference gel electrophoresis (2D-DIGE) and MALDI-TOF peptide mass fingerprinting were used to determine differentially expressed proteins between LoVo human colon carcinoma cell line and one of its MDR sublines (LoVo-R1). Thirty-four differentially expressed proteins were identified. They were classified into five groups based on their biological functions: i) proteins involved in energy request pathways, ii) in detoxification pathways, iii) in cell survival activity, iv) in drug transport and v) in chaperone functions. Among these proteins, endothelin 1 and proteasome subunit β2 regulations were validated by immunofluorescence and Western blotting, respectively, showing complete consistency with 2D-DIGE results. In conclusion, the proteomic approach indicates that multiple mechanisms are simultaneously involved in MDR. These might be useful in the search for new forms of interventional therapeutic approaches for MDR reversal.